Please ensure Javascript is enabled for purposes of website accessibility

Pfizer Inks Nanotechnology Deal With BIND Therapeutics

By Tim Brugger - Apr 3, 2013 at 5:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharma leader could pay as much as $210 million plus royalties for the nanoengineered therapeutic.

Pfizer (PFE 1.00%) and privately held BIND Therapeutics have entered into an agreement whereby Pfizer has the option to jointly develop and commercialize selected BIND Accurin technologies, according to a press release issued today. According to BIND, Accurins use a nanoengineering platform to better target diseased tissues and cells, enhancing drug concentrations and minimizing exposure to surrounding healthy areas.

The agreement calls for Pfizer and BIND to work together in conducting the pre-clinical research, Pfizer then has the option of selecting and developing the Accurins of its choice. If Pfizer exercises its option, BIND could receive upfront and milestone payments of totaling $50 million, and an additional $160 million, if certain regulatory and sales objectives are met. Tiered royalty payments based on future sales are also possible, according to the announcement.

Rod MacKenzie, Pfizer's senior vice president and head of pharmatherapeutics R&D, said, "We look forward to working with the team at BIND Therapeutics to create targeted Accurins with the aim of optimizing the therapeutic potential of future small molecules." 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.41 (1.00%) $0.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.